Cic edizioni internazionali
Reviews in Oncology

Adjuvant hormone therapy in early breast cancer:
aromatase inhibitors and the perimenopausal status

Review, 29 - 32
Tag this article
Abstract
Enhanced HTML Full text PDF
In postmenopausal status the aromatase inhibitors (AIs) represent a standard treatment whereas not recommended in the pre- and perimenopause status.
The medical oncology community has to be warned about use of AIs in the perimenopausal status due to the paradoxical increase in the both gonadotropin and of estrogen serum levels induced by these agents. Moreover, AIs are not recommended for women who report cessation of menses after chemotherapy due to the possible resumption of ovarian function. Although several clinical trials have been conducted in the adjuvant setting of postmenopausal status, few data are available on the endocrine safety of AIs in the perimenopausal setting. Defining of the menopausal status of a woman who will be treated with adjuvant hormone therapy is essential to avoid unexpected increase of estrogen levels that could promote tumor regrowth.

Vol. 3 (No. 1) 2015 January - December

  1. Pregnancy in breast cancer survivors: safety and feasibility
    Stani S.C., Sini V.
    doi: 10.11138/rio/2015.1.5.105
Last Viewed articles: la lista degli ultimi x visitati.
  1. Adjuvant hormone therapy in early breast cancer:
    aromatase inhibitors and the perimenopausal status

    Moscetti L., Nelli F., Ruggeri E.M.
credits